

A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

1. diagnosis of invasive pulmonary aspergillosis that hasn't responded to treatment

Exclusion Criteria:

1. surgical or medical condition that makes participation difficult or potentially unsafe
2. require care in an intensive care unit

Conditions & Interventions

Interventions:

Drug: PC945, Drug: Placebo

Conditions:

Breathing, Lung & Sleep Health, Infectious Diseases

Keywords:

Clinics and Surgery Center (CSC), antifungal therapy, aspergillosis, fungal infection, lung infection, pulmonary aspergillosis

More Information

Description: The purpose of this study is to learn about the safety and efficacy of PC945 when given in combination with the antifungal therapy that is normally given for this condition, also known as the standard of care (SoC). This study will also assess how PC945 is processed in the body (e.g., distributed, transformed, and removed) by measuring the levels of PC945 in your blood and lungs; this is called pharmacokinetics (PK).

Study Contact: Lindsey Raymond - raymo139@umn.edu

Principal Investigator: Jo-Anne Young, MD

IRB

Number: STUDY00017568

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.